Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Rockland Immunochemicals Acquires Epi-Plus® Product Line

Published: Tuesday, April 09, 2013
Last Updated: Tuesday, April 09, 2013
Bookmark and Share
Rockland Immunochemicals, Inc. announced the acquisition of the Epi-Plus® antibody product line from 21st Century Biochemicals, Inc.

Epi-Plus® antibodies are widely regarded as the most well validated antibodies available for epigenetics research. All Epi-Plus® antibodies are multi-assay validated, including dot blot testing using modified peptide arrays, western blots, and chromatin immunoprecipitation (ChIP).

Current research in Epigenetics, the study of changes in gene expression or cellular phenotype, has shown that epigenetic pharmaceuticals could be a putative replacement or adjuvant therapy for currently accepted treatment methods such as radiation and chemotherapy. The global revenue market for epigenetics has been estimated at $2.6 Billion in 2012 and is expected to reach $8 Billion by 2017, a five-year CAGR of 25%.

"The acquisition of the Epi-Plus® product line expands Rockland’s Life Science Tools portfolio and will allow our customers to perform their research in a more efficient and effective manner, ultimately saving time and precious research dollars," commented Jim Fendrick, President and CEO of Rockland Immunochemicals. “The fact that the Epi-Plus® brand is co-owned by Novus Biologicals also allows us to expand the Rockland brand globally."

“As 21st Century Biochemicals continues to focus its efforts on providing US manufactured custom peptide and antibody solutions for its customers, we are pleased that the Epi-Plus® product line is a strong strategic fit for the Rockland portfolio,” added Dr. Jordan Fishman, President and CSO of 21st Century Biochemicals.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Rockland Awarded SBIR Funding
Company awarded grant to develop antibody-based point of care device for the diagnosis of sickle cell disease.
Tuesday, September 09, 2014
Rockland Immunochemicals Expands into 60,000 Square Foot Facility
Company expands laboratories to keep pace with growth.
Thursday, May 29, 2014
Rockland Immunochemicals Awarded Phase I SBIR Funding
SBIR grant to develop nanoprobes for in vivo imaging of cancer cells and tumors.
Tuesday, October 22, 2013
Rockland and LIMR Expand Licensing and Commercialization Relationship
Rockland will market established technologies including the CellCountEZ®, OxPhos™, RadDose™ and the Intracellular ThiolEZ™ assays.
Tuesday, October 30, 2012
Rockland Immunochemicals Awarded Phase II SBIR Funding
Company receives grant for 1 million dollars to develop Akt/mTOR signaling pharmacodynamics assay.
Tuesday, October 16, 2012
Rockland Immunochemicals and LDI Form Antibody Commercialization Partnership
Rockland will market LDI’s entire portfolio of LIMR monoclonal and polyclonal antibodies.
Monday, April 23, 2012
Rockland Immunochemicals and Emory University Sign Master Reagent Agreement
Rockland and Emory collaborate to develop novel antibodies and antibody based tools for cancer, cell signaling and chromatin research.
Friday, January 28, 2011
Rockland Immunochemicals Awarded Phase I Funding to Develop Generic Antibodies for the Treatment of Cancer
Rockland Immunochemicals Inc. have received a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health to develop generic antibodies “biosimilars” for the treatment of cancer.
Thursday, November 04, 2010
Scientific News
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Four Gut Bacteria Decrease Asthma Risk in Infants
New research by scientists at UBC and BC Children’s Hospital finds that infants can be protected from getting asthma if they acquire four types of gut bacteria by three months of age.
Escape Prevention
Studying flu virus structure brings us a step closer to a permanent vaccine.
New Molecular Marker for Killer Cells
Cell marker enables prognosis about the course of infections.
Editing Genes to Create HIV Killers
Seattle scientists have managed to genetically transform human cells in the lab from HIV targets to HIV killers, and the technique could have implications for cancer and other diseases.
Antibiotic Overuse Might be Why so Many People Have Allergies
The Centers for Disease Control and Prevention estimates that drug resistant bacteria cause 23,000 deaths and two million illnesses each year.
Molecular ‘Kiss Of Death’ Flags Pathogens For Destruction
Researchers have discovered that our bodies mark pathogen-containing vacuoles for destruction by using a molecule called ubiquitin, commonly known as the "kiss of death."
Opening the Door to Safer, More Precise Cancer Therapies
New method regulates when, and how strongly, cancer-killing therapeutic T cells are activated.
Vaccination On The Horizon For Severe Viral Infection Of The Brain
Researchers from the University of Zurich and the University Hospital Zurich reveal possible new treatment methods for a rare, usually fatal brain disease.
What Do Animal Viruses Have to Do with Human Health?
Simon Anthony studies animal infections to prevent outbreaks in people.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos